Stockreport

MiNK Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]

MiNK Therapeutics, Inc.  (INKT) 
PDF dosing imminently after prior phase I/II data showed dosing up to 1 billion cells was well tolerated with clinical signals (including rapid extubation, pathogen clearanc [Read more]